CTLA4 and melanoma: In the past decade, cancer immunotherapy, particularly immune checkpoint blockade with antibodies targeted to the checkpoint receptors CTLA-4 and PD-1, have shown remarkable response rates in some cancer types such as melanoma, non-small cell lung cancer and mismatch-repair deficient (dMMR) colorectal cancer (9).